Yuanming Xu
Pfizer (United States)(US)University of Pennsylvania(US)
Publications by Year
Research Areas
Immune Cell Function and Interaction, Immunotherapy and Immune Responses, T-cell and B-cell Immunology, Cancer Immunotherapy and Biomarkers, Endoplasmic Reticulum Stress and Disease
Most-Cited Works
- → Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade(2019)539 cited
- → CRISPR screen in regulatory T cells reveals modulators of Foxp3(2020)228 cited
- → Engineering the ovarian cycle using in vitro follicle culture(2015)124 cited
- → USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism(2018)100 cited
- → Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction(2023)97 cited
- → An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity(2021)96 cited
- → ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes(2018)69 cited
- → The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity(2016)69 cited
- → HRD1‐ERAD controls production of the hepatokine FGF21 through CREBH polyubiquitination(2018)66 cited
- → The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine–induced ER stress response(2019)58 cited